|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
A group of peptide-based, long-acting, stable, highly selective cholecystokinin 1 receptor (CCK-1R) agonists with the potential to treat obesity has been identified and characterized, based on systematic investigation of synthetic CCK-8 analogues with N-terminal linkage to fatty acids.
|
30624060 |
2019 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
The satiety effects and metabolic actions of cholecystokinin (CCK) have been recognized as potential therapeutic targets in obesity for decades.
|
30843875 |
2019 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Reduced ability of cholecystokinin (CCK) to induce satiation contributes to hyperphagia and weight gain in high-fat/high-sucrose (HF/HS) diet-induced obesity, and has been linked to altered gut microbiota.
|
30069617 |
2019 |
|
Obesity
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The theoretical case has been made for the development of a positive allosteric modulator (PAM) of the type 1 cholecystokinin receptor (CCK1R) having minimal intrinsic agonist activity to enhance meal-induced satiety for the treatment of obesity, while reducing the risk of side effects and/or toxicity.
|
30591538 |
2019 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
This paper describes the early history of Gastric Inhibitory Polypeptide, better referred to simply as GIP, from its isolation by purification from a crude preparation of CCK-PZ (cholecystokinin/pancreozymin) to its recognition as a key player in the pathogenesis of obesity and other metabolic disorders far removed from the enterogastrone properties by which it was originally identified.
|
31539554 |
2019 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review focuses on the recent and ongoing developments of CCK in the context of new therapies for obesity and type 2 diabetes.
|
29412823 |
2018 |
|
Obesity
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
On the other hand, TTI treatment decreased CCK-1R gene expression in obese animals compared with the obese group with no treatment (p = 0.027).
|
30537704 |
2018 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
CCK-8S (1.8 or 5.2 nmol/kg) did not alter food intake and meal pattern in DIO rats.
|
28724546 |
2017 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Reduced CCK sensitivity best correlated with elevated serum triglycerides in normal-weight participants and with low HDL concentrations and elevated glycated hemoglobin in obese and diabetic patients.<b>Conclusions:</b> CCK responsiveness varies widely across the population, with reduced signaling in patients with obesity and diabetes.
|
28592602 |
2017 |
|
Obesity
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
We also show that CREB directly targets the Cck promoter in islets from obese (Leptin(ob/ob)) mice.
|
25984632 |
2015 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Positive correlations were observed between TPH1, CCK, PYY, and nesfatin1 in nonobese and GOAT, ghrelin, TPH1, SERT, CCK, and PYY in humans with obesity (all P < 0.01).
|
26381270 |
2015 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
These studies underscore the potential of (pGlu-Gln)-CCK-8 for the treatment of obesity-diabetes and suggest modulation of NPY and melanocortin related pathways may be involved in the observed beneficial effects.
|
23315994 |
2013 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
This Commentary provides a context for the use of efficacy pipeline pharmacogenetics (PGx) in therapeutic programs.Jordan et al. published the results of an obesity trial with a cholecystokinin-A (CCK-A) receptor agonist and concluded that CCK-A by itself does not have a central role in long-term energy balance.
|
19295535 |
2009 |
|
Obesity
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Although CCK-1R polymorphisms with amino acid changes such as 21Gly to Arg, 71 Arg to Gly, and 364 Val to Ile were discovered in subjects with obesity and diabetes mellitus, these changes occur sporadically.
|
17584142 |
2007 |
|
Obesity
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In addition, beta3 adrenergic receptor gene polymorphism (Try64Arg) and cholecystokinin (CCK)-A receptor (R) gene polymorphism (-81A/G, -128G/T), which are both associated with obesity, were investigated.
|
16362631 |
2006 |
|
Obesity
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Polymorphism or mutations in the CCK receptors may be involved in type 2 diabetes mellitus and obesity.
|
11773861 |
2002 |
|
Obesity
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The integrity of the cholecystokinin receptor gene in gallbladder disease and obesity.
|
7489984 |
1995 |
|
Obesity
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Abnormal processing of the human cholecystokinin receptor gene in association with gallstones and obesity.
|
7557108 |
1995 |